Clinical trials on a novel new type 2 diabetes treatment lowered glucose, did not increase lipids, and was well tolerated in patients with the chronic disease. The drug is an investigative liver-selective glucokinase activator, or GK activator, referred to as TTP399. It is a key regulator of glucose homeostasis. It is a member of the Hexokinase family and is expressed in the endocrine cells of the Langerhans islets of the liver, in the L- and K-cells of the intestines, and in the neurons of the central nervous system, in particular the hypothalamus. GK modulates blood glucose by inducing glucose-stimulated insulin ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.